Engelmann G L, Dionne C A, Jaye M C
Department of Medicine and Cell Biology, Loyola University Chicago, Stritch School of Medicine, Maywood, Ill. 60153.
Circ Res. 1993 Jan;72(1):7-19. doi: 10.1161/01.res.72.1.7.
Proliferative growth of the ventricular myocyte (cardiomyocyte) is primarily limited to fetal and early neonatal periods of development. In concert with the neonatal "transition" from proliferative to hypertrophic growth, ventricular remodeling of the nonmyocyte compartment is characterized by increased extracellular matrix synthesis/deposition and capillary angiogenesis. A role for locally generated and bioactive ventricular acidic fibroblast growth factor (aFGF) in these processes is proposed and substantiated by the following: 1) colocalization of aFGF peptide and fibroblast growth factor receptor (flg) transcripts to the developing fetal cardiomyocyte by immunohistochemistry, immunoelectron microscopy, and in situ hybridization, 2) continued localization of aFGF peptide and transcripts to the neonatal/mature cardiomyocyte, and 3) localization of flg immunoreactivity and transcripts to specific neonatal ventricular nonmuscle cell types. Specific ventricular cell types at distinct developmental stages appear to be responsive to ventricular myocyte-derived aFGF (myocytes in the fetal heart and nonmyocytes/endothelial cells in the neonatal heart). These data indicate that expression of aFGF and one of its receptors (flg) are most pronounced in the fetal to early neonatal ventricle, the presence of both suggesting an autocrine/paracrine growth regulatory function. As the animal matures, ventricular capillary angiogenesis may be facilitated by "release" of cardiomyocyte-derived fibroblast growth factors into the surrounding extracellular space/matrix functioning as a "paracrine" angiogenic stimuli. Therefore, the results of our study suggest that myocyte-derived aFGF may function to increase the fetal ventricular cardiomyocyte population in absolute number as well as to facilitate the subsequent increase in capillary angiogenesis that occurs during cardiomyocyte maturation and ventricular remodeling.
心室肌细胞(心肌细胞)的增殖性生长主要局限于胎儿期和新生儿早期发育阶段。与新生儿从增殖性生长向肥厚性生长的“转变”相一致,非肌细胞区室的心室重塑表现为细胞外基质合成/沉积增加和毛细血管生成。本文提出并证实了局部产生的生物活性心室酸性成纤维细胞生长因子(aFGF)在这些过程中的作用,依据如下:1)通过免疫组织化学、免疫电子显微镜和原位杂交技术,aFGF肽和成纤维细胞生长因子受体(flg)转录本在发育中的胎儿心肌细胞中共定位;2)aFGF肽和转录本持续定位于新生儿/成熟心肌细胞;3)flg免疫反应性和转录本定位于特定的新生儿心室非肌肉细胞类型。不同发育阶段的特定心室细胞类型似乎对心室肌细胞衍生的aFGF有反应(胎儿心脏中的心肌细胞和新生儿心脏中的非肌细胞/内皮细胞)。这些数据表明,aFGF及其受体之一(flg)的表达在胎儿至新生儿早期心室中最为明显,两者的存在提示自分泌/旁分泌生长调节功能。随着动物成熟,心肌细胞衍生的成纤维细胞生长因子“释放”到周围细胞外空间/基质中,作为“旁分泌”血管生成刺激物,可能促进心室毛细血管生成。因此,我们的研究结果表明,肌细胞衍生的aFGF可能起到增加胎儿心室心肌细胞绝对数量的作用,同时促进随后在心肌细胞成熟和心室重塑过程中发生的毛细血管生成增加。